A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial) - Bortezomib for relapsed ALL (BZM-ALL-2)

Department of Pediatric Oncology, National Cancer Center Hospital0 个研究点目标入组 22 人开始时间: 2016年9月9日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients who received hematopoietic cell transplantation(only in high risk group of first relapse) 2) Patients who received allograft transplantation within 4 months(120 days) (only in expansion cohort) 3) Patients who received immunosuppressant within 14 days 4) Double cancer 5) Concurrent infection requiring systemic treatment at enrollment 6) Fever over 38.5 degrees Celsius 7) Pregnant or possibly pregnant women. Breastfeeding women. Men and women providing no consent to avoiding pregnancy during the study. 8) Determined as difficult to participate in the study because of complicated psychiatric disease or mental symptoms 9) The following complications or previous histories: Previous cardiac disease Patients with a history of continuous oxygen therapy required for treatment or a history of respiratory function impairment Patients with complications determined to seriously compromise conducting of the study (for example, uncontrollable diabetes) 10) CNS disorder 11) Down syndrome 12) Patients determined as ineligible for participation in the study by an investigator or a sub-investigator for other reasons

发起方

Department of Pediatric Oncology, National Cancer Center Hospital